News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2024

4 October, 2024 Change in the Board of Directors of Egetis Therapeutics News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
30 September, 2024 NOTICE OF EXTRAORDINARY GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL) News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
30 September, 2024 Egetis Therapeutics has successfully carried out directed share issuances amounting to SEK 300 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional
30 September, 2024 Egetis Therapeutics announces the intention to carry out directed share issuances of approximately SEK 300 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional
19 September, 2024 Egetis submits a patent application to the United States Patent and Trademark Office for “Processes of Preparation” of tiratricol News Corporate Information Other Corporate Information English IR Optional
6 September, 2024 Egetis highlights seven abstracts related to MCT8 deficiency, and two abstracts related to tiratricol and RTH-beta, published ahead of the Annual Meeting of the European Thyroid Association News Corporate Information Other Corporate Information English IR Optional
28 August, 2024 New post-hoc analysis reports effects of tiratricol on patient-centered outcome measures in patients with MCT8 deficiency News Corporate Information Other Corporate Information English IR Optional
22 August, 2024 Interim report Q2 2024 News English Regulatory MAR VPML Report Interim Q2 IR Optional
21 August, 2024 New data shows tiratricol (Emcitate®) treatment in patients with MCT8 deficiency is associated with survival benefits News Corporate Information Other Corporate Information English IR Optional
14 August, 2024 Egetis submits responses to the European Medicines Agency’s Day 120 List of Questions for the Marketing Authorisation Application for tiratricol (Emcitate®) News Corporate Information Other Corporate Information English IR Optional
17 July, 2024 European Thyroid Association recommends tiratricol (Emcitate®) as long-term therapy for all patients with MCT8 deficiency in new guidelines News Corporate Information Other Corporate Information English IR Optional
19 June, 2024 Egetis announces topline results of the Phase 2 Triac Trial II with Emcitate® (tiratricol) for MCT8 deficiency News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
3 June, 2024 Egetis awarded Promising Innovative Medicine designation in the UK for Emcitate® (tiratricol) for treatment of MCT8 deficiency News Corporate Information Other Corporate Information English IR Optional
6 May, 2024 Bulletin from Egetis Therapeutics’ Annual General Meeting 2024 News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
3 May, 2024 Interim report Q1 2024 News English Regulatory MAR Report Interim Q1 IR Optional
24 April, 2024 The Nomination Committee adjusts its proposal for the annual general meeting of Egetis Therapeutics AB (publ) News Corporate Information Nomination Committee English Regulatory Listing Regulation IR Optional
15 April, 2024 Egetis Therapeutics’ 2023 Annual Report published News English Regulatory VPML Report Annual IR Optional
29 March, 2024 NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL) News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
22 February, 2024 Year-End report January-December 2023 News English Regulatory MAR Report Interim Yearend IR Optional

2023

22 December, 2023 Egetis recruits Laetitia Szaller as General Counsel and Head of Compliance News Corporate Information Staff change English IR Optional
19 December, 2023 Egetis highlights recent major milestones, status of ReTRIACt trial and gives a corporate update at Investor Day in Stockholm today News Corporate Information Other Corporate Information English IR Optional
14 December, 2023 Egetis’ Investor Day on December 19: Agenda and Registration Details News Corporate Information Other Corporate Information English IR Optional
13 December, 2023 Egetis provides update on disease awareness and the Expanded Access Program for tiratricol (Emcitate) in the USA News Corporate Information Other Corporate Information English IR Optional
1 December, 2023 Save the Date: Egetis to host Investor Day on December 19, 2023 News Corporate Information Other Corporate Information English IR Optional
10 November, 2023 Egetis announces exclusive license agreement with Fujimoto to develop and commercialize Emcitate in Japan News Corporate Action Other English Regulatory MAR IR Optional
Next

Calendar and upcoming reports

October 25, 2024
Extraordinary general meeting

November 8, 2024
Interim Report Q3 2024 (7:00am CET)

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]